Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy

BACKGROUND: Immune checkpoint inhibitors, including antibodies against programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4), are being used with increasing frequency for the treatment of cancer. Immune-related adverse events (irAEs) including colitis, dermatitis, and pneumonitis a...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Immunother Cancer
Main Authors: Shiuan, Eileen, Beckermann, Kathryn E., Ozgun, Alpaslan, Kelly, Ciara, McKean, Meredith, McQuade, Jennifer, Thompson, Mary Ann, Puzanov, Igor, Greer, John P., Rapisuwon, Suthee, Postow, Michael, Davies, Michael A., Eroglu, Zeynep, Johnson, Douglas
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2017
Teme:
Case Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5319013/
https://ncbi.nlm.nih.gov/pubmed/28239462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0210-0
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki